Good Start Genetics completed the initial closing of a $14 million Series B Preferred Stock financing, which was led by existing investors OrbiMed Advisors, Safeguard Scientifics Inc., and SV Life Sciences. Proceeds from this financing will be used to augment commercial efforts for the Company’s pre-conception carrier screening tests, and to support continued R&D efforts around its proprietary technology platform for future applications.
Don Hardison, President and CEO of Good Start Genetics, said, “We are pleased to complete the initial closing of our second financing as it provides the necessary funding to position Good Start Genetics for the next phase of growth. We value the vote of confidence and continued support from our current stockholders and are fortunate to have such a supportive group of world-class investors on our side.”
As part of Good Start Genetics’ growth and commercialization initiatives, the company has expanded its senior management team in areas of Finance, Human Resources as well as Customer Care and Reimbursement.
Hardison continued, “We are honored to attract and promote such exceptionally talented, experienced and successful professionals to Good Start Genetics to complement our strong and experienced management team. Our high caliber team will be vital to growing and expanding our platform.”